Treatment of Multiple Sclerosis: A Review.
Treatment of Multiple Sclerosis: A Review.
复制标题
DOI：
10.1016/j.amjmed.2020.05.049
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Cree BAC
中科院分区：
文献类型：
--
作者：
Hauser SL;Cree BAC
多发性硬化症（MS）是中枢神经系统的自身免疫性脱髓鞘和神经变性疾病，并且是年轻成年人非创伤性神经系统残疾的主要原因。有效的管理需要多方面的方法来控制急性发作，管理进行性恶化，并补救与这种疾病相关的令人烦恼或致残的症状。所有形式的MS治疗的显著进展，特别是复发性疾病，已经有利地改变了许多患者的长期前景。在理解MS的免疫病理学方面也发生了概念上的转变，从纯粹的T细胞介导的模型到认识到B细胞在发病机制中具有关键作用。需要较低频率给药的更高疗效药物的出现使这些药物在耐受性和依从性方面成为首选。许多专家现在建议在永久性残疾明显之前，将这些药物作为许多早期疾病患者的一线治疗。
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system, and the leading cause of non-traumatic neurological disability in young adults. Effective management requires a multifaceted approach to control acute attacks, manage progressive worsening, and remediate bothersome or disabling symptoms associated with this illness. Remarkable advances in treatment of all forms of MS, and especially for relapsing disease, have favorably changed the long-term outlook for many patients. There also has been a conceptual shift in understanding the immune pathology of MS, away from a purely T-cell-mediated model to recognition that B cells have a key role in pathogenesis. The emergence of higher-efficacy drugs requiring less frequent administration have made these preferred options in terms of tolerability and adherence. Many experts now recommend use of these as first-line treatment for many patients with early disease, before permanent disability is evident.
登录
查看更多内容
影响因子：
11.2
作者：
Cree, Bruce A. C.;Hollenbach, Jill A.;Hauser, Stephen L.
通讯作者：
Hauser, Stephen L.
影响因子：
158.5
作者：
Hauser, S. L.;Bar-Or, A.;Kappos, L.
通讯作者：
Kappos, L.
影响因子：
168.9
作者：
Coles, Alasdair J.;Twyman, Cary L.;Compston, D. Alastair S.
通讯作者：
Compston, D. Alastair S.
影响因子：
158.5
作者：
Cohen, Jeffrey A.;Barkhof, Frederik;Kappos, Ludwig
通讯作者：
Kappos, Ludwig
影响因子：
9.9
作者：
Cadavid, D.;Wolansky, L. J.;Cook, S. D.
通讯作者：
Cook, S. D.